Percutaneous vertebroplasty for osteoporotic vertebral body fractures

Akio Hiwatashi Per-Lennart Westesson

University of Rochester Medical Center

Learning objectives

- 1. To learn the indication, technique and prognosis of percutaneous vertebroplasty for osteoporotic vertebral fractures.
- 2. To understand the medical management and background of the patients who require repeat vertebroplasty

Osteoporosis: Definition

- reduction of bone mass (or density) or
- presence of a fragility fracture
 - T-score of >2.5 SD below mean for young healthy adults of the same race and gender
 - Osteoporosis
 - T-score of >1 SD below mean
 - low bone density
 - increased risk of osteoporosis.

Osteoporosis: introduction

- Chief clinical manifestations
 - vertebral and hip fractures
 - affects >10 million inUS
 - 55% in US >50y
 - 17 billions/year medical cost

- Symptomatic vertebral fx
 - More than hip fx
 - 1.23/1000 person/year
 - 26% in women >50y
 - only a small proportion are diagnosed and treated

Osteoporosis: Fractures Overview

- Vertebral Fx: 700,000/year in US
 - rarely require hospitalization
 - long-term morbidity and slight increase in mortality.
 - Thoracic Fx: restrictive lung disease
 - Lumbar Fx: abdominal symptoms (distention, early satiety, and constipation)
- Distal radius Fx
 - increase before age 50 and plateau by age 60
- Hip Fx: doubles every 5 years after age 70
 - The probability is 14% for women and 5% for men
 - the risk for African Americans is lower (about half these rates)

Osteoporosis Approach to the patient (1/2)

- Routine Laboratory Evaluation
 - No established algorithm for osteoporosis
- CBC, serum (urine) calcium
 - Serum Ca↑: hyperparathyroidism or malignancy
 - PTH↑: hyperparathyroidism
 - PTHrP
 †: humoral hypercalcemia of malignancy
 - Serum Ca↓: malnutrition and osteomalacia.
 - Urine Ca↓: osteomalacia, malnutrition, or malabsorption
 - Urine Ca↑:
 - renal calcium leak-males with osteoporosis
 - absorptive hypercalciuria- idiopathic or associated with increased 1,25(OH)2D in granulomatous disease
 - hematologic malignancies or excessive bone turn over (Paget's disease, hyperparathyroidism, and hyperthyroidism)

Osteoporosis Approach to the patient (2/2)

- TSH
 - hyperthyroidism
- Cortisol
 - Cushing's syndrome
- Albumin, Cholesterol, CBC
 - bowel disease, malabsorption, or malnutrition
- Antigliadin, Antiendomysial, or transglutaminase antibodies
 - Celiac disease (may require endoscopic biopsy)
- Histamine or tryptase
 - Mastocytosis
- X-ray, light chains

Osteoporosis: Fx management

- Hip or long bone Fxs
 - surgical repair if the patient is to become ambulatory again
- Other Fxs (e.g., vertebra, rib, and pelvIS)
 - supportive care
 - analgesics including NSAIDS and/or acetaminophen
 - Sometimes narcotic agent (codeine or oxycodone)
 - vertebroplasty or kyphoplasty; significant immediate pain relief in the majority of patients. Long-term effects are unknown
 - elastic-style brace
 - muscle relaxants and heat treatments.
- Severe pain usually resolves within 6 to 10 weeks

Osteoporosis: Risk factors

- Age
- Gender
- Family history
- Race
- Small body size
- Early menopause
- Smoking

- Alcohol
- No exercise
- Steroids
- Anticonvulsant
- Methotrexate
- Cyclosporin
- Heparin

Osteoporosis: Underlyning disease

- Reduce risk factors
 - Glucocorticoid and thyroid hormone should be as low as possible
 - smoking cessation
 - alcohol abuse treatment
 - review of the medical regimen
 - orthostatic hypotension and/or sedation

Osteoporosis Recommendation

- Nutrition
 - Calcium
 - Vitamin D

Exercise

Osteoporosis Tx for Underlying disease

- Estrogen
 - oral or transdermal
- Progestin
 - In women with a uterus (To reduce uterine cancer)
 - daily or cyclical at least 12 days per month
 - On breast tissue, progestins may increase the risk of breast cancer.

- Bisphosphonates
 - Alendronate
 - Risedronate
- Calcitonin
- Parathyroid hormone
- Selective estrogen response modulators (SERMs)
 - Raloxifene
 - osteoporosis
 - Tamoxifen
 - breast cancer.

Osteoporosis: Steroid

Widely used

COPD, RA, IBD, and posttransplantation

Mechanisms

- inhibition of osteoblast function and an increase in osteoblast apoptosis, resulting in impaired synthesis of new bone
- stimulation of bone resorption
- impairment of the absorption of calcium
- increase of urinary calcium loss
- reduction of adrenal androgens and suppression of ovarian and testicular estrogens and androgens
- induction of glucocorticoid myopathy

Tx

- bisphosphonates
 - Risedronate
 - Alendronate
 - Etidronate

Vertebroplasty Background

- First reported in 1984 for aggressive hemangioma
- Expanded to osteoporosis, metastasis, tumor




Vertebroplasty Indication (PE)

- Patients who failed conservative Tx
 - most patients were treated 6–12 weeks
- Focal discomfort at palpation
- Absence of radicular symptoms or neurologic deficits
- Vertebral osteonecrosis (Kummell Disease)

Vertebroplasty Preoperative Imaging

- Plain Film
- CT
- MR
 - edema/enhance
- Bone scan
 - uptake



Vertebroplasty Complications

< 5%

- Bleeding
- Infection
- Damage
 - Fx of pedicle, ribs
 - Compression of nerve roots/spinal cord
- Pulmonary embolism

Vertebroplasty Technique


- Fluoroscopy (or CT)
- bipedicular or monopedicular approach
- 13-gauge bone biopsy needle(s) placed into the anterior 1/3 of the vertebral body
- polymethylmethacrylate
- barium sulfate
- Antibiotics (e.g. tobramycin)
- until the vertebral body was filled toward the posterior 20% of the vertebral body or leakage
- Patient remains prone until the cement will be hard





Vertebroplasty Postoperative imaging

- Plain Film
- CT
 - Most useful
 - Leakage evaluation
- MRI
- Bone scan



Vertebroplasty mechanism for pain relief

- Stabilization preventing intravertebralmotion
- Chemical destruction of nocicepters
- Thermal destruction of nocicepters

Vertebroplasty Outcome

73-95% of pain relief

- 10-25% developed new vertebral body fractures following treatment
 - Often seen in adjacent vertebrae

Vertebroplasty Cause for repeat Tx

- 53 pts (36 F and 17 M; mean 79 years)
 - 35 pts treated once
 - 18 pts treated more than once
- Main difference
 - presence of chronic steroid use
 - no significant differences
 - Age
 - Gender
 - Use of medical treatment

Take home message

- Vertebroplasty is a safe and effective for treatment of osteoporotic vertebral fracture
- Chronic steroid use can cause repeat fractures

Suggested readings

- Mathis JM, Barr JD, Belkoff SM, Barr MS, Jensen ME, Deramond H.
 Percutaneous vertebroplasty: a developing standard of care for vertebral compression fractures. AJNR Am J Neuroradiol 2001; 22:373-381
- Kallmes DF, Jensen ME.
 Percutaneous vertebroplasty. Radiology. 2003 Oct;229(1):27-36.
- Uppin AA, Hirsch JA, Centenera LV, Pfiefer BA, Pazianos AG, Choi IS.
 Occurrence of new vertebral body fracture after percutaneous vertebroplasty in patients with osteoporosis. Radiology. 2003 Jan;226(1):119-24.
- Syed MI, Patel NA, Jan S, Harron MS, Morar K, Shaikh A. New symptomatic vertebral compression fractures within a year following vertebroplasty in osteoporotic women. AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1601-4.
- McGraw JK, Cardella J, Barr JD, Mathis JM, Sanchez O, Schwartzberg MS, Swan TL, Sacks D; SIR Standards of Practice Committee Society of Interventional Radiology quality improvement guidelines for percutaneous vertebroplasty.
 - J Vasc Interv Radiol. 2003 Jul;14(7):827-31.
- Miller DA, Fenton DS, Dion JE. Vertebroplasty. In: Fenton DS, Czervionke LF, ed. Image-guided spine intervention. Philadelphia, Pa: Sauders, 2003; 189-225.
- Harrison's Principles of Internal Medicine, 16th Edition